Avior Wealth Management LLC Purchases 7,658 Shares of Becton, Dickinson and Company $BDX

Key Points

• Avior Wealth Management LLC increased its holdings in Becton, Dickinson and Company by 2,934.1%, purchasing an additional 7,658 shares, bringing its total to 7,919 shares worth approximately $1.36 million.
• Becton, Dickinson and Company reported a quarterly EPS of $3.68, exceeding analysts' expectations of $3.40, with revenues of $5.51 billion for the quarter.
• The company announced a quarterly dividend of $1.04 per share, resulting in an annual yield of 2.3%, with an upcoming payment date on September 30th.

Avior Wealth Management LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2,934.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,919 shares of the medical instruments supplier's stock after purchasing an additional 7,658 shares during the period. Avior Wealth Management LLC's holdings in Becton, Dickinson and Company were worth $1,364,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. GQG Partners LLC bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $689,833,000. Vanguard Group Inc. boosted its position in Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares during the period. Nuveen LLC acquired a new position in shares of Becton, Dickinson and Company in the first quarter valued at $211,097,000. Kingstone Capital Partners Texas LLC bought a new position in shares of Becton, Dickinson and Company in the second quarter valued at about $155,080,000. Finally, GAMMA Investing LLC lifted its stake in shares of Becton, Dickinson and Company by 29,654.0% during the 1st quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier's stock worth $170,523,000 after buying an additional 741,943 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company's stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,965 shares of company stock valued at $551,536. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

BDX opened at $184.59 on Monday. The firm has a market cap of $52.91 billion, a P/E ratio of 33.20, a price-to-earnings-growth ratio of 1.49 and a beta of 0.27. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The business's fifty day moving average is $188.27 and its 200-day moving average is $188.49.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research note on Thursday. They set a "sector perform" rating and a $211.00 target price on the stock. Barclays dropped their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Argus upped their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Finally, Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and an average target price of $213.09.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.